ETF vs Index Mutual Fund: Which One's Better?
ETFs and index mutual funds are very simliar, but a few small differences can mean a lot to investors.
2 Reasons Alnylam Stock Fell on a Landmark Drug Approval
Investors didn't celebrate Alnylam's first drug approval. Maybe they should have.
3 Top Tech Stocks to Buy in August
Looking for a few great buys in the tech sector? Start here.
Shorting is a part of a healthy stock market, but it's usually best left to professionals.
The synthetic biology pioneer announced a secondary share offering and the exercise of warrants.
Shares pop after the company reports upbeat fourth-quarter results. Here's what investors need to know.
Is there enough opportunity in sports betting and Japan to make up the difference?
Canopy Growth, Cronos Group, and Tilray have captured the imagination of growth investors. But can the blistering growth of their share prices continue, or is it time to take profits?
Magellan Midstream Partners, HCP Inc., and Brookfield Infrastructure Partners look like great retirement stocks.
The retailer just logged its best sales growth in over a decade.
The country's leading multiplex operator signed up more than a quarter-million AMC Stubs A-List subscribers in just seven weeks. MoviePass is failing at just the right time.
This company's leading a race that's drawn a lot of competition.
You have to be discreet and ethical.
The GPU specialist turned in great Q2 results, but its stock sank nearly 5% in after-hours trading on Thursday due to its Q3 revenue outlook coming in lighter than Wall Street was anticipating.
If you want value investments in today's stock market, take a look at LGI Homes and ExxonMobil.
Alphabet has reigned over the search kingdom for a long time, but voice presents a new paradigm. Will a new ruler be crowned?
The company is on pace for its ninth straight year of growth.
One pot stock could approach $700 million in full-year sales.
Which of these two bank stocks is more attractive?
The parent of Tinder is surging after its latest earnings report. Here's what investors should know.
Could another huge deal be on the way after Constellation's $4 billion investment in Canopy? Investors seem to think so.
Next-generation biotech products could threaten the existence of agricultural nutrient producers, but few seem to be taking notice.
Listening to some commonly heard advice cost me more than $23,000. Here's how you can learn from my mistake.